Polyrizon (PLRZ) Stock Analysis
NASDAQHealthcareBiotechnology
What Polyrizon does
Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.
Key metrics
ETFs linked to PLRZ
Broad-market and Healthcare sector ETFs an investor holding Polyrizon is often also exposed to. Open an ETF page to see its actual top holdings.
PortView Portfolio Insights
PortView analyzes how PLRZ fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.
Analyze PLRZ in PortView →Similar companies
Frequently asked questions
- What is the ticker symbol for Polyrizon?
- Polyrizon trades under the ticker PLRZ on NASDAQ.
- Which exchange is PLRZ listed on?
- PLRZ is listed on NASDAQ.
- What sector does Polyrizon operate in?
- Polyrizon is classified in the Healthcare sector (Biotechnology industry).
- How can PortView help analyze PLRZ in a portfolio?
- PortView shows PLRZ's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.
The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.